Commercialization of a novel tool for designing personalized nOvel MelAnoma Therapies

Project Information

COMbAT

Grant agreement ID: 677645

DOI 10.3030/677645

Project closed

EC signature date 10 September 2015

Start date 1 October 2015

End date 31 March 2017

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost € 150 000,00

EU contribution € 150 000,00

Coordinated by

WEIZMANN INSTITUTE OF SCIENCE
Israel

Publications

Peer reviewed articles (1)

Recurrent inactivating RASA2 mutations in melanoma

Author(s): Rand Arafeh, Nouar Qutob, Rafi Emmanuel, Alona Keren-Paz, Jason Madore, Abdel Elkahloun, James S Wilmott, Jared J Gartner, Antonella Di Pizio, Sabina Winograd-Katz, Sivasish Sindiri, Ron Rotkopf, Ken Dutton-Regester, Peter Johansson, Antonia L Pritchard, Nicola Waddell, Victoria K Hill, Jimmy C Lin, Yael Hevroni, Steven A Rosenberg, Javed Khan, Shifra Ben-Dor, Masha Y Niv, Igor Ulitsky, Graham J M
Published in: Nature Genetics, Issue 47/12, 2015, Page(s) 1408-1410, ISSN 1061-4036
Publisher: Nature Publishing Group
DOI: 10.1038/ng.3427

Intellectual Property Rights

Other (1)

VECTORS, COMPOSITIONS AND METHODS FOR ENDOGENOUS EPTOPE TAGGING OF TARGET GENES FIELD OF THE INVENTION

Application/Publication number: PCT IL2016/050035
Date: 2016-07-21
Applicant(s): WEIZMANN INSTITUTE OF SCIENCE